Journal Information
Vol. 33. Issue. 3.May 2013
Pages 0-735
Full text access
A comment on the question 'Are the aims of the K/DOQI guidelines for mineral metabolism disorders in stages 3-5 chronic kidney disease unachievable or inadequate?'
Comentario a ¿Son inalcanzables o inadecuados los objetivos de las guías K/DOQI en las alteraciones del metabolismo mineral en pacientes con enfermedad renal crónica 3-5?
Visits
...
Armando L. Negria
a Servicio de Nefrología, Instituto de Investigaciones Metabólicas. Universidad del Salvador, Buenos Aires, Argentina,
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Content

To the Editor:

I read with much attention and a great deal of interest the editorial by Dr. Elvira Fernández1 on whether the aims of the K/DOQI guidelines on mineral metabolism disorders in stages 3-5 chronic kidney disease are unachievable or inadequate. Dr. Fernández concludes that the recommended values are adequate but unachievable at the time the OSERCE I study was conducted, since no drugs such as oral paricalcitol, sevelamer carbonate or lanthanum carbonate were available for use in pre-dialysis.

However, I believe that the evidence on the adequacy of the mineral metabolism parameter values is not clearly defined by any prospective study as the KDIGO guidelines demonstrate: neither are stage 3 and 4 parathyroid hormone values clear, nor is it clear whether or not we should maintain 25(OH)D values > 30ng/ml or whether or not we should use non-calcium chelating agents in pre-dialysis. The study by Block GA et al.2 on the effects of phosphorus chelating agents in moderate renal failure using calcium and non-calcium chelating agents is very disturbing, given the association between high levels of phosphorus and mortality. The conclusion of that study was that phosphorus chelating agents significantly lowered serum and urinary phosphorus and slowed the progression of secondary hyperparathyroidism in patients with moderate chronic renal failure (CRF) with normal or near normal levels of phosphorus, but that it nevertheless promoted progression of vascular calcification, which called into question the effectiveness and safety of phosphorus chelating agents in stage 3-4 CRF. We require well-designed comprehensive prospective studies that use hard endpoints such as total and cardiovascular mortality to assess what mineral metabolism values are adequate and what interventions can be carried out to achieve them safely.

 

Conflicts of interest

The author declares potential conflicts of interest.

Lecture fees: Abbot; Sanofi.

Council Membership: Consejo de Metabolismo Mineral de la Asociación Nefrológica de Buenos Aires.

Bibliography
[1]
Fernández E. ¿Son inalcazables o inadecuados los objetivos de las guías K/DOQI en las alteraciones del metabolismo mineral en pacientes con enfermedad renal crónica 3-5? Nefrologia 2013;33(1):1-6.
[2]
2. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23(8):1407-15.  
Idiomas
Nefrología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?